| Protocol |
Title |
Status |
Contact |
| 103989 |
A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors |
OPEN TO ACCRUAL |
 |
| 104031 |
Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma |
OPEN TO ACCRUAL |
|
| 104013 |
A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103834 |
Phase 1 Dose Escalation Study for a Trispecific Antibody (SAIL66), Targeting Solid Tumors Expressing CLDN-6 and CD3/CD137+ T-cells |
OPEN TO ACCRUAL |
|
| 103936 |
Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) |
OPEN TO ACCRUAL |
|
| 103966 |
A Phase I/Randomized Phase II, Open-Label Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of mFOLFIRINOX With or Without BNT321 as Adjuvant Therapy Following Curative Resection in Patients with Pancreatic Adenocarcinoma |
OPEN TO ACCRUAL |
|
| 103905 |
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART |
OPEN TO ACCRUAL |
|
| 104067 |
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study |
OPEN TO ACCRUAL |
|
| 103913 |
3068/217908 A Phase III Randomized Trial of Heated Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
OPEN TO ACCRUAL |
|
| 103868 |
A Randomized, Phase 2, Open-label Study of TransCon IL-2 B/y Monotherapy, TransCon IL-2 B/y in Combination with TransCon TLR7/8 Agonist, TransCon TLR7/8 Agonist in Combination with Pembrolizumab, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) |
OPEN TO ACCRUAL |
|
| 103979 |
Phase I trial of Methotrexate, Rituximab, Lenalidomode, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma |
OPEN TO ACCRUAL |
|
| 103517 |
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer |
OPEN TO ACCRUAL |
|
| 103948 |
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|
| 103739 |
A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications |
OPEN TO ACCRUAL |
|
| 104046 |
NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial |
OPEN TO ACCRUAL |
|
| 104039 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117 or Placebo in Combination with Azacitidine in Patients With Newly Diagnosed Higher-Risk Myelodysplastic Syndromes |
OPEN TO ACCRUAL |
|
| 103898 |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
OPEN TO ACCRUAL |
|
| 103923 |
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103478 |
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) |
OPEN TO ACCRUAL |
|
| 103974 |
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors |
OPEN TO ACCRUAL |
|